Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 5/20 | 0.50 |
| ▸ | PPARA | Q07869 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5537439 | 0.86 | HRH3 (0.61) | KDM4EHRH3HPGDPPARGPPARA | |
| SCHEMBL266619 | 0.84 | KDM4E (0.66) | KDM4EHRH3HPGDPPARGPPARA | |
| SCHEMBL5537753 | 0.83 | HRH3 (0.58) | KDM4EHRH3HPGDPPARGPPARA | |
| SCHEMBL5540713 | 0.83 | HSD17B10 (0.53) | KDM4EHPGDPPARALMNATP53 | |
| SCHEMBL3996100 | 0.83 | TARBP2 (0.50) | KDM4EHRH3HPGDPPARGPPARA | |
| SCHEMBL5544269 | 0.82 | PPARG (0.57) | KDM4EHRH3HPGDPPARGPPARA | |
| SCHEMBL503999 | 0.82 | KDM4E (0.64) | KDM4EHRH3HPGDPPARGPPARA | |
| SCHEMBL4037331 | 0.82 | KDM4E (0.69) | KDM4EHRH3HPGDPPARGPPARA | |
| SCHEMBL3756029 | 0.82 | KDM4E (0.64) | KDM4EHRH3HPGDPPARGPPARA | |
| SCHEMBL6776092 | 0.82 | KDM4E (0.64) | KDM4EHRH3HPGDPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575911-B1 | BIAROMATIC COMPOUNDS WHICH ACTIVATE PPAR-GAMMA TYPE RECEPTORS AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RES & DEV (FR) | 2010-01-13 | — | — | EP | claimed |
| US-7452878-B2 | Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-11-18 | — | — | US | claimed |
| US-20050256116-A1 | Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-11-17 | — | — | US | claimed |
| US-20040152746-A1 | Treatment of scarring and related conditions using ppar-gamma activators | ARACHNOVA THERAPEUTICS LTD. (JE) | 2004-08-05 | — | — | US | claimed |
| EP-1385516-A1 | THE TREATMENT OF SCARRING AND RELATED CONDITIONS USING PPAR-GAMMA ACTIVATORS | Arachnova Therapeutics Ltd. (GB) | 2004-02-04 | — | — | EP | claimed |
| WO-2002087576-A1 | THE TREATMENT OF SCARRING AND RELATED CONDITIONS USING PPAR-GAMMA ACTIVATORS | ARACHNOVA THERAPEUTICS LTD. (GB) | 2002-11-07 | — | — | WO | claimed |
| CN-107441096-A | Applications of the RS 504393 in preparing treatment gemcitabine chemotherapy and interrupting the medicine of carcinoma of urinary bladder | 上海市第人民医院 | 2017-12-08 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7919515-B2 | 3-phenylpropionic acid derivatives | ADAMED SP. Z O.O. (PL) | 2011-04-05 | — | — | US | disclosed |
| WO-2010141696-A1 | METHODS OF TREATING OR PREVENTING PSORIASIS, AND/OR ALZHEIMER'S DISEASE USING INDANE ACETIC ACID DERIVATIVES | DARA BIOSCIENCES, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| US-7807669-B2 | Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-10-05 | — | — | US | disclosed |
| EP-1833805-B1 | NEW 3-PHENYLPROPIONIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES | ADAMED SP ZOO (PL) | 2010-02-10 | — | — | EP | disclosed |
| WO-2006067086-A1 | NEW 3-PHENYLPROPIONIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES | ADAMED SP. Z O.O. (PL) | 2006-06-29 | — | — | WO | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| US-20050256116-A1 | Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-11-17 | — | — | US | disclosed |
| EP-1575911-A2 | BIAROMATIC COMPOUNDS WHICH ACTIVATE PPAR-GAMMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2005-09-21 | — | — | EP | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004046091-A2 | BIAROMATIC COMPOUNDS WHICH ACTIVATE PPAR-GAMA TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152746-A1 | Treatment of scarring and related conditions using ppar-gamma activators | PPARA, PPARD, PPARG | KDM4E 2717/4885HRH3 3345/4885HPGD 762/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | KDM4E 4854/4885HRH3 420/4885HPGD 3159/4885 |
| US-20050256116-A1 | Novel biaromatic compounds which activate PPARy type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARA, PPARD | KDM4E 3167/4885HRH3 801/4885HPGD 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.